In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d.

Mourad, Omar; Chagla, Zain

Mourad, Omar; Chagla, Zain.

Mourad O; McMaster University, Hamilton, Ontario, Canada (O.M., Z.C.).
Chagla Z; McMaster University, Hamilton, Ontario, Canada (O.M., Z.C.).

Ann Intern Med ; 175(5): JC50, 2022 05.

Article in English | MEDLINE | ID: covidwho-1835633

ABSTRACT

ABSTRACT

SOURCE CITATION Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386305-15. 34937145.

Subject(s)

Adenosine Monophosphate/pharmacology; Alanine/pharmacology; COVID-19 Drug Treatment; Adenosine Monophosphate/analogs & derivatives; Alanine/analogs & derivatives; Hospitalization; Humans; Outpatients; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adenosine Monophosphate / Alanine / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google